Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)

Chugai Pharmaceutical

Status and phase

Completed

Phase 3

Conditions

Hemodialysis Patients

Treatments

Drug: R744

Study type

Interventional

Funder types

Industry

Identifiers

NCT00433888

JH20563

Details and patient eligibility

About

This study will assess the efficacy and safety of intravenous R744 in renal anemia patients on hemodialysis.

Enrollment

179 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who have been receiving hemodialysis 3 times a week for at least 12 weeks before registration
Patients aged ≥ 20 years at the time of obtaining consent Patients who have been receiving a rHuEPO preparation at least once a week for at least 8 weeks before registration
Patients whose mean value of Hb concentrations determined before the first dialysis of each week within 8 weeks prior to the registration has been between ≥ 10.0 g/dL and <12.0 g/dL
Patients whose transferrin saturation has been ≥ 20 % or ferritin has been
- 100ng/mL at any one time point within 8 weeks before registration

Exclusion criteria

Patients with hardly controllable hypertension (patients whose diastolic blood pressure has been ≥ 100 mmHg on more than 1/3 of the determining occasions within 12 weeks before registration)
Patients with congestive cardiac failure (≥ Class III in NYHA cardiac function classification)
Female patients who are pregnant, lactating, possibly pregnant or not willing to take a contraceptive measure in the period from the day of starting the treatment with the study drug to 90 days after the day of the last dose of the study drug
Patients with complication of myocardial infarction, pulmonary infarction or cerebral infarction (excluding asymptomatic cerebral infarction)
Patients confirmed to have serious allergy or serious drug allergy (shock, anaphylactoid symptom)
Patients hypersensitive to a rHuEPO preparation
Patients with malignant tumor (including hemic malignant tumor), severe infection, systemic hemic disease (osteomyelodysplasia syndrome, hemoglobinopathy, etc.), hemolytic anemia or apparent hemorrhagic lesion such as digestive tract hemorrhage
Patients who have received an anabolic hormone preparation, testosterone enanthate or mepitiostane within 12 weeks before registration
Patients who have received another investigational drug within 12 weeks before registration
Patients who have received R744 before registration
Patients whose AST(GOT) value ≥ 100 IU/L or ALT(GPT) value ≥ 100 IU/L before registration
Patients who have received erythrocyte transfusion within the last 16 weeks before registration
Patients for whom a surgical operation involved with heavy bleeding is planned during the study period
In addition, patients who are judged as ineligible to participate in this study by the investigator or sub-investigator